These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23344238)

  • 1. Targeted siRNA Delivery and mRNA Knockdown Mediated by Bispecific Digoxigenin-binding Antibodies.
    Schneider B; Grote M; John M; Haas A; Bramlage B; Ickenstein LM; Jahn-Hofmann K; Bauss F; Cheng W; Croasdale R; Daub K; Dill S; Hoffmann E; Lau W; Burtscher H; Ludtke JL; Metz S; Mundigl O; Neal ZC; Scheuer W; Stracke J; Herweijer H; Brinkmann U
    Mol Ther Nucleic Acids; 2012 Sep; 1(9):e46. PubMed ID: 23344238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific digoxigenin-binding antibodies for targeted payload delivery.
    Metz S; Haas AK; Daub K; Croasdale R; Stracke J; Lau W; Georges G; Josel HP; Dziadek S; Hopfner KP; Lammens A; Scheuer W; Hoffmann E; Mundigl O; Brinkmann U
    Proc Natl Acad Sci U S A; 2011 May; 108(20):8194-9. PubMed ID: 21536919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific Antibodies for Targeted Delivery of Dendritic Polyglycerol (dPG) Prodrug Conjugates.
    Mehrabadi FS; Adelmann J; Gupta S; Wedepohl S; Calderón M; Brinkmann U; Haag R
    Curr Cancer Drug Targets; 2016; 16(7):639-49. PubMed ID: 26853135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hapten-Binding Bispecific Antibodies for the Targeted Delivery of SiRNA and SiRNA-Containing Nanoparticles.
    Thorey IS; Grote M; Mayer K; Brinkmann U
    Methods Mol Biol; 2016; 1364():219-34. PubMed ID: 26472454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes.
    Chen IJ; Cheng YA; Ho KW; Lin WW; Cheng KW; Lu YC; Hsieh YC; Huang CC; Chuang CH; Chen FM; Su YC; Roffler SR; Cheng TL
    Acta Biomater; 2020 Jul; 111():386-397. PubMed ID: 32417267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient and Highly Specific Gene Transfer Using Mutated Lentiviral Vectors Redirected with Bispecific Antibodies.
    Parker CL; Jacobs TM; Huckaby JT; Harit D; Lai SK
    mBio; 2020 Jan; 11(1):. PubMed ID: 31964730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
    French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
    Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.
    Urbanska K; Lynn RC; Stashwick C; Thakur A; Lum LG; Powell DJ
    J Transl Med; 2014 Dec; 12():347. PubMed ID: 25496493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
    Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
    J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
    Park JA; Cheung NV
    J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opportunities and challenges of bi-specific antibodies.
    Segués A; Huang S; Sijts A; Berraondo P; Zaiss DM
    Int Rev Cell Mol Biol; 2022; 369():45-70. PubMed ID: 35777864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
    Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
    Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binary and ternary complexes based on polycaprolactone-graft-poly (N, N-dimethylaminoethyl methacrylate) for targeted siRNA delivery.
    Huang Y; Lin D; Jiang Q; Zhang W; Guo S; Xiao P; Zheng S; Wang X; Chen H; Zhang HY; Deng L; Xing J; Du Q; Dong A; Liang Z
    Biomaterials; 2012 Jun; 33(18):4653-64. PubMed ID: 22480869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of gene targeting siRNAs to breast cancer cells using a multifunctional peptide complex that promotes both targeted delivery and endosomal release.
    Bjorge JD; Pang A; Fujita DJ
    PLoS One; 2017; 12(6):e0180578. PubMed ID: 28666009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells.
    Khare P; Dave KM; Kamte YS; Manoharan MA; O'Donnell LA; Manickam DS
    AAPS J; 2021 Dec; 24(1):8. PubMed ID: 34873640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain.
    Schoonjans R; Willems A; Schoonooghe S; Leoen J; Grooten J; Mertens N
    Biomol Eng; 2001 Jun; 17(6):193-202. PubMed ID: 11337278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
    Michaelson JS; Demarest SJ; Miller B; Amatucci A; Snyder WB; Wu X; Huang F; Phan S; Gao S; Doern A; Farrington GK; Lugovskoy A; Joseph I; Bailly V; Wang X; Garber E; Browning J; Glaser SM
    MAbs; 2009; 1(2):128-41. PubMed ID: 20061822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
    Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
    Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
    Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
    Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.